BioSpace News Archive

Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that Camilla V. Simpson has joined Dyve’s Board of Directors.

– Topline data on track for targeted readout before the end of Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment –

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and Drug Administration (“FDA”) to include new information in the product label for AMZEEQ ® (minocycline) topical foam, 4% referencing the low propensity of P. acnes strains to develop resistance

Reflect Scientific, Inc., a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announces a new ultra-low temperature freezer addition to the Cryometrix product line that can be rapidly deployed in a transportable, self-powered configuration.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020 , at 4:00 p.m. Eastern Time .

BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the appointment of Jamie Donadio as Chief Financial Officer.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) has commenced sales and marketing activities for the Eversense® XL CGM system in key European markets

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs).

T3/C15 enriched cannabis fraction inhibits liver fibrosis Findings add to Can-Fite’s expertise and assets in the treatment of liver disease including liver cancer and NASH

AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17 th Annual WORLD Symposium ™ 2021 Analyst and investor event scheduled for Monday, Feb. 8 at 8:00 a.m. ET Four platform presentations and two posters on the company’s clinical and preclinical programs for lysosomal disorders are scheduled throughout 17 th annual WORLDSymposium™